SEC Form 4 · accession 0001209191-17-063895
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqualyn A Fouse
Director
Period of report
Dec 3, 2017
Accepted (ET)
Dec 5, 2017 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $61.17 | Dec 3, 2017 | A | 16,000 | A | — | Dec 2, 2027 | Common stock | 16,000 | 16,000 | D |
Explanation of responses
- F1This option was granted on December 3, 2017. The shares underlying this option vest as to 25% of the underlying shares on December 2, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.